A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers

PURPOSE: Determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. METHODS: Phase II study in adenoid cystic (ACC) and non-adenoid cystic (non-ACC) carcinomas. Gefitinib was administered 250mg oral...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Head Neck
Prif Awduron: Jakob, John A., Kies, Merrill S., Glisson, Bonnie S., Kupferman, Michael E., Liu, Diane D., Lee, J. Jack, El-Naggar, Adel K., Gonzalez-Angulo, Ana M., Blumenschein, George R.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2015
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5669372/
https://ncbi.nlm.nih.gov/pubmed/24585506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.23647
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg